Shares of Cassava Sciences shares soared 141% on Tuesday after the biotechnology company circulated promising data from the study simufilam that is assessing its drug candidate for the treatment of Alzheimer’s disease.
An analysis that is interim of medical study showed an improvement in patients’ cognition function following 6 months of simufilam therapy. Research participants’ cognition scores enhanced by 10% an average of from baseline. Better still, these clients’ dementia-related symptoms, such as for instance agitation and anxiety, improved by the average of 29% from standard.
Importantly, no safety that is serious were reported during the study.
The outcomes had been especially impressive, as Alzheimer’s is a disease that is progressive causes the cognitive abilities of the whom experience it to decrease in the long run.
“we might were pleased to exhibit simufilam stabilizes cognition in clients over half a year,” CEO Remi Barbier stated in a PR release. “a marked improvement in cognition and behavior tells us this drug candidate has potential to provide treatment that is enduring for folks coping with Alzheimer’s condition.”
Cassava Sciences promises to start a phase 3 trial that is medical of into the second half of 2021. Should the therapy continue to show the capability to improve cognition function safely in individuals with Alzheimer’s, its market potential would likely be enormous. Nearly 6 million people within the U.S. alone have problems with the memory-destroying infection, and you will find presently no drugs in the marketplace that can halt its development.
“An improvement in cognition and behavior tells us this medication prospect has prospective to produce treatment that is enduring for folks managing Alzheimer’s illness.” The stock has run up seven-fold (up 604.5%) over the past 90 days, whilst the S&P 500 SPX, +1.39% has gained 15.9%. Shares of Cassava Sciences shares soared 141% on Tuesday.